Consistent with these results, biopsies from NSCLC patients who had received neoadjuvant cisplatin revealed increased PD-L1 expression after cisplatin treatment, while anti-PD-L1 treatment in mouse models in vivo effectively inhibited tumor growth (40). This evidence concerns the gene CD274 and non-small cell lung carcinoma.